| __timestamp | Alnylam Pharmaceuticals, Inc. | Travere Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 190249000 | 47795223 |
| Thursday, January 1, 2015 | 276495000 | 50426000 |
| Friday, January 1, 2016 | 382392000 | 70853000 |
| Sunday, January 1, 2017 | 390635000 | 78168000 |
| Monday, January 1, 2018 | 505420000 | 123757000 |
| Tuesday, January 1, 2019 | 655114000 | 140963000 |
| Wednesday, January 1, 2020 | 654819000 | 131773000 |
| Friday, January 1, 2021 | 792156000 | 210328000 |
| Saturday, January 1, 2022 | 883015000 | 235780000 |
| Sunday, January 1, 2023 | 1004415000 | 244990000 |
| Monday, January 1, 2024 | 1126232000 |
Unleashing insights
In the competitive world of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Alnylam Pharmaceuticals, Inc. and Travere Therapeutics, Inc. have demonstrated contrasting strategies in their R&D investments.
Since 2014, Alnylam has consistently increased its R&D budget, culminating in a 428% rise by 2023. This surge underscores their aggressive pursuit of groundbreaking therapies, positioning them as a leader in RNA interference technology.
Conversely, Travere's R&D spending has grown by 413% over the same period, reflecting a more measured approach. Their focus on rare diseases has driven steady investment, ensuring sustainable growth and innovation.
These trends highlight the diverse strategies within the biotech sector, where both rapid and steady R&D investments can lead to significant advancements.
Research and Development: Comparing Key Metrics for Amgen Inc. and Alnylam Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for argenx SE and Alnylam Pharmaceuticals, Inc.
Analyzing R&D Budgets: Alnylam Pharmaceuticals, Inc. vs Genmab A/S
Analyzing R&D Budgets: Alnylam Pharmaceuticals, Inc. vs Bio-Techne Corporation
R&D Spending Showdown: Alnylam Pharmaceuticals, Inc. vs Ascendis Pharma A/S
R&D Spending Showdown: Genmab A/S vs Travere Therapeutics, Inc.
Research and Development: Comparing Key Metrics for Jazz Pharmaceuticals plc and Travere Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Ionis Pharmaceuticals, Inc. and Travere Therapeutics, Inc.
Analyzing R&D Budgets: Verona Pharma plc vs Travere Therapeutics, Inc.
Research and Development Investment: Viking Therapeutics, Inc. vs Travere Therapeutics, Inc.
Research and Development: Comparing Key Metrics for Protagonist Therapeutics, Inc. and Travere Therapeutics, Inc.
Analyzing R&D Budgets: Travere Therapeutics, Inc. vs Xencor, Inc.